TICKERNERD
Menu
SYRESYREHealthcare · Biotechnology

SYRE Stock Forecast: Spyre Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$89
+1.98% on the day

The 16 Wall Street analysts covering Spyre Therapeutics, Inc. hold a median 12-month price target of $121 — +36.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 7 Sept 2026 — in the lower half.

Market cap
$7.7B
Ticker Nerd rank
46 / 100
Median analyst target
$121
Analysts covering
16
Revenue$0.0
Operating income−$81.6M
Net income−$36.2M
Free cash flow−$69.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.5%
1M
−15.2%
YTD
+171.6%
1Y
+423.7%
From 52W high
−18.3%
From 52W low
+500.4%
$15
$109
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SYRE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spyre Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Value
79
Quality
72
Volatility
54
Growth
48
Revisions
48
Issuance
28
Size
18
Accruals
16

Momentum (96): The shares have been drifting up relative to others.

Accruals (16): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SYRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SYRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26SYREHigh $130Median $121Low $97

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $97Median $121High $130

The green dot is the last close — the median target sits +36.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
26 Aug 2026BTIGMaintainsBuy$132 → $121
26 Aug 2026Deutsche BankMaintainsBuy$135 → $127
26 Aug 2026WedbushMaintainsOutperform$130 → $123
11 Aug 2026BTIGMaintainsBuy—
11 Aug 2026BTIGMaintainsBuy$112 → $132
5 Aug 2026GuggenheimMaintainsBuy$115 → $130
5 Aug 2026GuggenheimMaintainsBuy—
5 Aug 2026WedbushMaintainsOutperform$100 → $130
5 Aug 2026WedbushMaintainsOutperform—
5 Aug 2026Wells FargoMaintainsOverweight$90 → $115
5 Aug 2026Wells FargoMaintainsOverweight—
28 July 2026Wolfe ResearchDowngradePeer Perform—
28 July 2026Wolfe ResearchDowngradePeer Perform—
13 July 2026MizuhoMaintainsOutperform—
13 July 2026MizuhoMaintainsOutperform$84 → $120
23 June 2026Deutsche BankMaintainsBuy—
15 June 2026BTIGMaintainsBuy—
4 June 2026Deutsche BankMaintainsBuy—
6 May 2026CitigroupMaintainsBuy—
6 May 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SYRE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SYRE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Spyre Therapeutics, Inc. returned +423.7% against +20.0% for the S&P 500, dividends included.

SYRE vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Oct 25Jan 26Apr 26Jul 26SYRES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SYRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
9
Analysts cutting
3
Fundamentals

Spyre Therapeutics, Inc. (SYRE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.7×

Cheaper than 70% of US stocks

Price / sales
—
Price / book
8.2×

Cheaper than 12% of US stocks

EV / EBITDA
−29.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−23.0%

Higher than 30% of US stocks

Return on assets
−19.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Spyre Therapeutics, Inc. (SYRE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spyre Therapeutics, Inc. has a market value of $7.7B and an enterprise value of $6.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$178.9M.

  • Diluted earnings per share, trailing twelve months: $−2.05.

  • Free cash flow in the twelve months to 30 June 2026: −$208.9M.

  • Shares outstanding: 88.1M.

  • Trailing P/E: 1.7×; forward P/E: −25.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Spyre Therapeutics, Inc. employs 125 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

SYRE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SYRESpyre Therapeutics, Inc.$7.7B
46
IMVTImmunovant, Inc.$7.9B
40
TWSTTwist Bioscience Corp.$8.2B
62
CAICaris Life Sciences, Inc.$7.1B
32
RYTMRhythm Pharmaceuticals, Inc.$7.1B
88
IBRXImmunityBio, Inc.$8.5B
50
PCVXVaxcyte, Inc.$8.7B
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Spyre Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SYRE news & analysis

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

GlobeNewsWire · 8 Sept 2026positive

Spyre announced that SPY003 (anti-IL-23) met its primary endpoint in Part A of the SKYLINE trial, with a statistically significant reduction of 10.0 points, completing proof-of-concept for all three components of its IBD combinations.

Why it matters — This completes proof-of-concept across all components of Spyre's IBD combination programs, marking a notable milestone for SYRE watchers.

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewsWire · 4 Sept 2026neutral

Spyre Therapeutics' independent Compensation Committee approved an equity inducement award for a non-executive employee, consisting of stock options to purchase 2,106 shares and 745 restricted stock units, granted under the company's 2018 Equity Inducement Plan. The award was approved on September 1, 2026 and was material to the employee's acceptance of employment, in line with Nasdaq Listing Rule 5635(c)(4).

Why it matters — SYRE watchers would care because this routine equity grant reflects the company's standard practice of using inducement awards to attract and secure key new hires.

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Spyre Therapeutics announced that its management will participate in three upcoming investor conferences in September 2026: the Citi BioPharma Back to School Conference, the Wells Fargo Healthcare Conference, and the Stifel Virtual Immunology and Inflammation Forum. Management will also host one-on-one investor meetings during these events.

Why it matters — The company's participation in these investor conferences and one-on-one meetings provides opportunities for Spyre's management to present its clinical-stage immunology pipeline to the investment community.

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 3 Sept 2026negative

Spyre Therapeutics reported earnings about 30 days ago, and its stock has declined 16.6% since that report. Zacks Investment Research examines the company's results and discusses whether the stock could rebound.

Why it matters — SYRE watchers would be interested in the stock's post-earnings decline and the outlook following its most recent quarterly results.

SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

Zacks Investment Research · 26 Aug 2026negative

Spyre's SPY072 showed activity in rheumatoid arthritis, but the benefit was smaller than expected, leading SYRE stock to fall. The company is shifting its focus toward broader autoimmune uses and combination therapies.

Why it matters — SYRE watchers would care because the underwhelming RA data has pressured the stock and redirected the company's strategic focus toward other autoimmune indications and combinations.

FAQ

Frequently asked questions about SYRE stock

What is the SYRE stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Spyre Therapeutics, Inc. have a median 12-month price target of $121, with estimates ranging from $97 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SYRE stock a buy right now?

Of the 16 analysts covering Spyre Therapeutics, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spyre Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SYRE?

As at 7 Sept 2026, Spyre Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will SYRE stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +36.0% from the last close, and Ticker Nerd's factor model ranks Spyre Therapeutics, Inc. 46 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SYRE stock forecast for 2030?

No analyst covering Spyre Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SYRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $97 to $130 over the next 12 months.

How has SYRE stock performed over the past year?

Spyre Therapeutics, Inc. returned +423.7% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Spyre Therapeutics, Inc. do?

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders.

What is the latest news on SYRE?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations". Spyre announced that SPY003 (anti-IL-23) met its primary endpoint in Part A of the SKYLINE trial, with a statistically significant reduction of 10.0 points, completing proof-of-concept for all three components of its IBD combinations.

Company

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment durability, and simplify dosing for patients with ulcerative colitis, Crohn’s disease, and related rheumatic conditions. Its current pipeline centers on investigational antibody programs targeting key immune pathways, including α4β7, TL1A, and IL-23, with both standalone and combination approaches under development. The company is primarily engaged in biopharmaceutical research and clinical development, and its work is centered on creating next-generation immunology treatments for complex chronic diseases. Headquartered in Waltham, Massachusetts, Spyre Therapeutics serves as a specialized player in the biotech sector, where it contributes to the advancement of targeted therapies for gastrointestinal and immune-mediated diseases.

CEO Dr. Cameron Turtle DPHIL, Ph.D. · 125 employees · United States · https://www.spyre.com